Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.010
-0.060 (-5.61%)
Jan 28, 2026, 1:48 PM EST - Market open
Skye Bioscience Employees
Skye Bioscience had 16 employees as of December 31, 2024. The number of employees increased by 5 or 45.45% compared to the previous year.
Employees
16
Change (1Y)
5
Growth (1Y)
45.45%
Revenue / Employee
n/a
Profits / Employee
-$3,201,833
Market Cap
32.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 16 | 5 | 45.45% |
| Dec 31, 2023 | 11 | 0 | - |
| Dec 31, 2022 | 11 | 2 | 22.22% |
| Dec 31, 2021 | 9 | 3 | 50.00% |
| Dec 31, 2020 | 6 | 2 | 50.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Evaxion | 46 |
| Cue Biopharma | 41 |
| Werewolf Therapeutics | 39 |
| AN2 Therapeutics | 22 |
| Outlook Therapeutics | 17 |
| Genenta Science | 13 |
| Serina Therapeutics | 13 |
SKYE News
- 7 days ago - Skye Bioscience to Present Poster at Keystone Obesity Conference - GlobeNewsWire
- 12 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Newsfile Corp
- 14 days ago - INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - GlobeNewsWire
- 15 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - Newsfile Corp
- 16 days ago - Skye Provides 2026 Corporate Outlook - GlobeNewsWire
- 19 days ago - SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience - GlobeNewsWire
- 23 days ago - Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity - PRNewsWire
- 5 weeks ago - Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE. - Business Wire